Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration

By afschroeder • December 9, 2025

Rosen LS, Ottensmeier C, Hawkins M, Naing A, Sonpavde G, Van Tine BA, Parkes EE, O'Cathail SM, Ji RR, Thomas M, Stacey A, Sasso MS, Rosen O. Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration. J Immunother Precis Oncol. 2025 Nov 25;8(4):263-275. doi: 10.36401/JIPO-25-18. PMID: 41358276; PMCID: PMC12681188.

Tags: Hematology/Oncology, immunotherapy, oncolytic immunotherapies, Publications, solid tumors, Tolerability, viral persistence

Related Posts

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar[...]

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin[...]